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Abstract
A 27-year-old male underwent total thyroidectomy for thyroid swelling. Histopathology showed papillary thyroid 
carcinoma [T3 - 6.0 cm] with extra-thyroidal extension. The patient was treated with 150 mCi radioactive iodine 
(RAI) as adjuvant ablative therapy. Radioiodine refractory disease was identified 1-year post-RAI therapy with 
elevated thyroglobulin levels and negative I-131 whole body scan. F-18 FDG positron emission tomography/computed 
tomography scan showed activity in the right thyroid bed and multilevel right cervical nodes. Right-sided modified 
neck dissection was done, which showed Castleman disease (hyaline vascular type) in right cervical nodes. The 
most probable cause of elevated tumour markers was found out to be 0.6 cm right thyroid bed nodule on follow-up 
ultrasonography. Our patient also had coexistent conditions as; osteopoikilosis and Hepatitis C along with thyroid 
carcinoma.
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Introduction
Castleman disease (CD) first described in 1956[1] is a rare 
lymphoproliferative disorder with diverse manifestations 
which can affect any organ. CD is a great mimicker of benign 
and malignant conditions.[2] As in our patient, who was 
initially treated for papillary carcinoma thyroid. However, 
after the initial treatment with surgery and radioactive 
iodine therapy, patient developed radio-iodine refractory 
disease (RRD) resulting in no Iodine uptake on whole body 
scan although tumor markers were elevated. F-18 FDG 
PET-CT scan was performed to evaluate RRD and showed 
hypermetabolic lymph nodes. These were histologically 
proven to be involved with Castleman disease.
Case Report
A 27-year-old male presented with 3-year history of anterior 
neck swelling. Radionuclide Tc-99m thyroid scan showed a 
cold nodule. Fine-needle aspiration and cytology (FNAC) 
suggested a follicular neoplasm Bethesda category-IV 
thyroid lesion. Hepatitis C (HCV) positivity was found 
incidentally on a pre-surgical screening test. The patient 
underwent total thyroidectomy which confirmed papillary 
thyroid carcinoma (PTC) [T3 - 6.0 cm] with extrathyroidal 
extension. Baseline stimulated thyroglobulin (Tg) was 
95 ng/ml. Post-operative whole body scan (WBS) showed 
multifocal I131 avid thyroid remnant and patient was treated 
with 150 mCi radioactive iodine (RAI) as adjuvant ablative 
therapy. Stimulated Tg levels 1-year post-therapy was 
354 ng/ml. However, I131WBS did not reveal Iodine-avid 
disease indicating radioiodine-refractory disease (RRD). 
F-18 FDG positron emission tomography/computed 
tomography (PET/CT) scan showed subtle metabolic activity 
in the right thyroid bed with multilevel hypermetabolic 
right cervical nodes, suggesting active disease with de-
differentiation [Figure 1]. Right-sided modified neck 
dissection was done. Histopathology revealed Castleman 
disease (CD) (hyaline vascular type) in right cervical nodes 
with no evidence of malignancy or granulomatous disease. 
The patient remained on clinical follow-up. Ultrasound neck 
showed a 0.6 cm right thyroid bed nodule which was most 
likely the cause for elevated tumour markers. In addition, 
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baseline and follow-up investigations (magnetic resonance 




Historically in 1956, Dr. Benjamin Castleman described 
CD for the 1st time.[1] CD is a rare lymphoproliferative 
disorder with diverse manifestations which may affect 
any organ. Therefore, it is a great mimicker of benign and 
malignant conditions.[2] Only a few such cases are reported 
in literature.[3] CD is a non-cancerous, lymphoproliferative 
disorder which may have unicentric (UCD) or multicentric 
(MCD) presentation.[4] MCD may exist as benign disease 
or pre-malignant disease which may transform into 
Hodgkin’s lymphoma with poorer outcome. UCD disease 
is categorised as histologic evidence of CD in only 
one lymph node group with no clinical or radiographic 
evidence of lymphadenopathy elsewhere. On the other 
hand, MCD is categorised by histologic evidence of CD 
in one lymph node group with radiographic or clinical 
evidence of lymphadenopathy in other regions as well.[5] In 
our patient, CD was found out in the right-sided levels II, 
III, and IV lymph nodes. Right-sided cervical nodal chain 
was the only side of FDG avidity on PET CT. Therefore, 
our patient was categorised under UCD.
Our patient is also a unique case where various independent 
entities coexist, i.e., thyroid cancer - PTC, OPK, HCV, 
and CD. A review of literature shows no dependence 
or correlation between these entities except in between 
chronic/untreated HCV and CD. Chronic/untreated viral 
infection, i.e., HCV, EBV, and HHV-8 could initiate the 
systemic inflammatory response possibly leading to the 
development of CD.[5] In our patient, the presence of HIV, 
EBV, or HHV-8 was not checked.
The diagnosis is made on histopathological features 
of excised affected lymph nodes. If excision is 
not possible, core needle biopsy is preferred over 
FNAC.[6] Histopathological subtypes include hyaline 
vascular, plasma cell, mixed, and plasmoblastic subtypes.[7] 
Histologically our patient shows hyalinevascular subtype 
which is characterised by an increased number of small, 
hyalinised blood vessels present within or in-between the 
follicles [Figure 2].
There is an increase in lymphoid follicles with a 
predominance of dendritic cells within germinal centres as 
compared to lymphocytes. These features cause broadening 
of mantle zones. Two interesting features, which are part of 
the morphological spectrum are: (1) The onion skinning, 
(blue arrow) which is formed by small lymphocytes in 
the mantle zones arranged in concentric rings around the 
germinal centre and (2) lollipop follicles (black arrow), 
which are actually the follicles radially penetrated by 
blood vessels. Plasma cells are found in small clusters. 
The cases of plasma cell variant CD show greater retention 
of the nodal architecture with hyperplastic follicles of 
variable sizes and focally patent medullary sinuses. The 
inter-follicular region characteristically contains sheets of 
mature-appearing plasma cells.[8]
The disease mainly involves the mediastinum and 
abdomen. Peripheral involvement, especially of the 
Figure 1: (a-c) F-18 FDG positron emission tomography/
computed tomography sagittal and coronal whole body fusion 
images showed hypermetabolic right level-II, III, and VI cervical 
lymph nodes with a standardised uptake value of 2.8 (thin arrow), 
these nodes represented Castleman disease. Focal uptake in the 
thyroidectomy bed with SUV of 4.8 (thick arrow) is residual 
thyroid disease
a b c
Figure 2: (a and b) Histopathology of our patient shows 
typical Onion skinning (blue arrow), which is formed by 
small lymphocytes of the mantle zones, arranged in concentric 
rings around the germinal centre and lollipop follicles (black 
arrow). Which are actually the follicles radially penetrated by 
blood vessels
a b
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head and neck region, is rare. Differentials include 
lymphadenitis, tuberculosis, sarcoidosis, toxoplasmosis, 
cytomegalovirus, mononucleosis, HIV, and some tumours 
such as neurofibroma, cervical lipoma, Hodgkin’s disease, 
thymoma, non-Hodgkin’s lymphoma, and lymph nodal 
metastasis from head and neck malignancies.[9] The disease 
is staged before start of treatment to help in determining 
the centricity of disease, associated inflammatory 
manifestations, conditions, and malignancies. Staging 
helps in choosing appropriate treatment modalities. There 
are variable treatment options for UCD and MCD disease. 
Common sites of presentation in UCD include the chest 
(30%), neck (23%), abdomen (20%), retroperitoneum 
(17%) and rarely, the axilla (5%), groin (3%), or pelvis 
(2%). Surgery is the established gold standard for the 
treatment of UCD.
Most UCD cases get a complete or partial response 
with surgery. While MCD cases respond to various 
chemotherapeutic agents, monoclonal antibodies, 
glucocorticoids, and thalidomide. Radiotherapy has also 
been reported to be effective in some patients with a 
variable response rate.[10-13]
Papillary thyroid cancer
PTC is the most common type of differentiated thyroid 
cancer with an excellent prognosis. A small percentage of 
PTC has the tendency to behave aggressively and develop 
into RRD.[14,15] The modality of choice for imaging RRDis 
FDG PET-CT scan.[16] Our patient represents an FDG avid 
case of CD unrelated to thyroid cancer. The elevated Tg 
levels were attributed to a sub centimetre recurrent right 
thyroid bed nodule. However, due to the small size of 
recurrent tissue, it could not be surgically resected.
Osteopoikilosis
OPK is rare benign condition manifesting as multifocal 
bone islands. It is usually incidentally found on radiographs 
or CT [Figure 3]; normal scintigraphic uptake on MDP 
bone scan strengthens the diagnosis by excluding bone 
metastasis.[17,18] Although OPK is largely asymptomatic, 
15–20% of patients present with slight articular pain and 
joint effusion.[19] No definite pathogenesis is defined. 
However, multiple hypotheses have been suggested as 
hereditary failure to form normal trabeculae along the lines 
of stress, dysplasia of endochondral ossification, which can 
result in focal densities or striations within the trabecular 
bone, loss-of-function mutations in LEMD3 gene, and 
altered osteogenesis.[20] First described in 1915 by Albers-
Schonberg,[21] OPK usually has multiple, sclerotic, round or 
oval foci with symmetrical distribution in periarticular areas 
within the epiphyseal and metaphyseal regions. However, 
slight variation is also noted in a few cases as in our patient.
In addition, thyroid cancer metastases are known to be 
lytic rather than dense sclerotic lesions. This feature, as 
well as lack of RAI and FDG PET/CT scan uptake in our 
patient, differentiated it from metastases.
Conclusion
CD is a potential mimicker of FDG avid metastatic disease 
on F18-FDG PET/CT scan in a variety of malignancies 
including undifferentiated thyroid cancer.
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